^
    7d
    An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma (clinicaltrials.gov)
    P1/2, N=40, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was closed early as the sponsor decided not to continue development of certain treatment combinations.
    Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Tecentriq (atezolizumab) • capecitabine • oxaliplatin • tiragolumab (RG6058)
    9d
    UmbrellaMAX: A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study (clinicaltrials.gov)
    P3, N=100, Recruiting, Hoffmann-La Roche | N=23 --> 100
    Enrollment change
    |
    Avastin (bevacizumab) • Rozlytrek (entrectinib) • ipatasertib (RG7440) • divarasib (RG6330) • Itovebi (inavolisib) • tiragolumab (RG6058)
    14d
    SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China. (PubMed, J Thorac Oncol)
    While results from the global SKYSCRAPER-02 study were not statistically significant, numerical improvements in PFS and OS were seen with tiragolumab plus atezolizumab plus CE versus atezolizumab plus CE in Chinese patients with ES-SCLC. Biomarker analysis identified immune-inflamed signatures that may guide future TIGIT-based strategies.
    Clinical • P3 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • tiragolumab (RG6058)
    1m
    INDIGO: Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures (clinicaltrials.gov)
    P2, N=0, Withdrawn, Gustave Roussy, Cancer Campus, Grand Paris | N=115 --> 0 | Trial completion date: Jan 2030 --> Sep 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2028 --> Sep 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    1m
    SKYSCRAPER-05: A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=50, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was terminated as data became available from Phase 3 trials of perioperative regimens combining chemotherapy with immunotherapy showing improved efficacy outcomes versus chemotherapy alone.
    Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • gemcitabine • paclitaxel • pemetrexed • tiragolumab (RG6058)
    2ms
    Specific depletion of TIGIThigh CD226- clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. (PubMed, J Immunother Cancer)
    Targeted elimination of clonally expanded intratumoral Tregs is essential to unlock the full therapeutic potential of αTIGIT. These novel findings provide a key rationale and strategic direction for overcoming the limitations of current αTIGIT-based cancer immunotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • CD226 (CD226 Molecule)
    |
    tiragolumab (RG6058)
    2ms
    Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P2, N=0, Withdrawn, National Cancer Institute (NCI) | N=36 --> 0 | Trial completion date: Jun 2027 --> Aug 2025 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2026 --> Aug 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    RAS wild-type
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2ms
    A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, M.D. Anderson Cancer Center | N=35 --> 4 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Checkpoint inhibition
    |
    CD4 (CD4 Molecule)
    |
    BostonGene Tumor Portrait™ Test
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2ms
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • axitinib • tiragolumab (RG6058) • tobemstomig (RG6139)
    3ms
    SKYLINE: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | N=130 --> 81
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PD-L1 negative • ER negative
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • tiragolumab (RG6058)
    3ms
    Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial. (PubMed, ESMO Gastrointest Oncol)
    Secondary endpoints include feasibility, safety, post-operative complications, and metabolic response by positron emission tomography. Exploratory studies characterize immune cell infiltration, tumor mutational burden, and circulating tumor DNA dynamics.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    3ms
    SKYSCRAPER-15: A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (clinicaltrials.gov)
    P3, N=56, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)